These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 24820095)

  • 21. Management of osteoporosis in postmenopausal women: 2010 position statement of The North American Menopause Society.
    Menopause; 2010; 17(1):25-54; quiz 55-6. PubMed ID: 20061894
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective.
    Boonen S; Marin F; Mellstrom D; Xie L; Desaiah D; Krege JH; Rosen CJ
    J Am Geriatr Soc; 2006 May; 54(5):782-9. PubMed ID: 16696744
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Real-world challenges of treating osteoporosis.
    Owens G
    Am J Manag Care; 2011 May; 17 Suppl 6():S177-84. PubMed ID: 21882487
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bisphosphonates: safety and efficacy in the treatment and prevention of osteoporosis.
    Greenspan SL; Harris ST; Bone H; Miller PD; Orwoll ES; Watts NB; Rosen CJ
    Am Fam Physician; 2000 May; 61(9):2731-6. PubMed ID: 10821153
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment.
    Prince R; Sipos A; Hossain A; Syversen U; Ish-Shalom S; Marcinowska E; Halse J; Lindsay R; Dalsky GP; Mitlak BH
    J Bone Miner Res; 2005 Sep; 20(9):1507-13. PubMed ID: 16059622
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Osteoporosis in older men: recent advances in pathophysiology and treatment.
    Laurent M; Gielen E; Claessens F; Boonen S; Vanderschueren D
    Best Pract Res Clin Endocrinol Metab; 2013 Aug; 27(4):527-39. PubMed ID: 24054929
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Osteoporosis: Common Questions and Answers.
    Harris K; Zagar CA; Lawrence KV
    Am Fam Physician; 2023 Mar; 107(3):238-246. PubMed ID: 36920813
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.
    Liberman UA; Weiss SR; Bröll J; Minne HW; Quan H; Bell NH; Rodriguez-Portales J; Downs RW; Dequeker J; Favus M
    N Engl J Med; 1995 Nov; 333(22):1437-43. PubMed ID: 7477143
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis.
    Gallagher JC; Rosen CJ; Chen P; Misurski DA; Marcus R
    Bone; 2006 Dec; 39(6):1268-75. PubMed ID: 16884968
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assessing compliance, acceptance, and tolerability of teriparatide in patients with osteoporosis who fractured while on antiresorptive treatment or were intolerant to previous antiresorptive treatment: an 18-month, multicenter, open-label, prospective study.
    Adachi JD; Hanley DA; Lorraine JK; Yu M
    Clin Ther; 2007 Sep; 29(9):2055-67. PubMed ID: 18035204
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Teriparatide--new value in osteoporosis treatment: treatment guidelines].
    Korsić M; Kastelan D
    Reumatizam; 2006; 53(2):77-81. PubMed ID: 17580560
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Established and forthcoming drugs for the treatment of osteoporosis.
    Lems WF; Geusens P
    Curr Opin Rheumatol; 2014 May; 26(3):245-51. PubMed ID: 24625372
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Teriparatide: new preparation. Osteoporosis: less well evaluated than alendronic acid.
    Prescrire Int; 2005 Feb; 14(75):5-9. PubMed ID: 15747448
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Osteoporosis in older persons: current pharmacotherapy and future directions.
    Duque G
    Expert Opin Pharmacother; 2013 Oct; 14(14):1949-58. PubMed ID: 23885760
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women.
    Wensel TM; Iranikhah MM; Wilborn TW
    Pharmacotherapy; 2011 May; 31(5):510-23. PubMed ID: 21923432
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Up-to-date treatments for osteoporosis].
    Bors K
    Orv Hetil; 2006 Feb; 147(7):301-6. PubMed ID: 17489157
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Asia-pacific consensus on osteoporotic fracture prevention in postmenopausal women with low bone mass or osteoporosis but no fragility fractures.
    Huang CF; Chen JF; Reid IR; Chan WP; Ebeling PR; Langdahl B; Tu ST; Matsumoto T; Chan DC; Chung YS; Chen FP; Lewiecki EM; Tsai KS; Yang RS; Ang SB; Huang KE; Chang YF; Chen CH; Lee JK; Ma HI; Xia W; Mithal A; Kendler DL; Cooper C; Hwang JS; Wu CH
    J Formos Med Assoc; 2023; 122 Suppl 1():S14-S20. PubMed ID: 36775679
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The bone anabolic therapy.
    Nardi A; Ventura L; Cozzi L; Tonini G; Zennaro R; Celi M; Ramazzina E
    Aging Clin Exp Res; 2013 Oct; 25 Suppl 1():S121-4. PubMed ID: 24078441
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Osteoporosis diagnosis and medical treatment.
    Warriner AH; Saag KG
    Orthop Clin North Am; 2013 Apr; 44(2):125-35. PubMed ID: 23544819
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Osteoporosis and Fragility Fractures: currently available pharmacological options and future directions.
    Dimai HP; Fahrleitner-Pammer A
    Best Pract Res Clin Rheumatol; 2022 Sep; 36(3):101780. PubMed ID: 36163230
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.